127423-61-4

Basic information

• Product Name: ethyl 2-chloro-4-ethoxy-nicotinate
• Synonyms: ethyl 2-chloro-4-ethoxy-nicotinate;(R)-3-[(Methylsulfonyl)oxy]pyrrolidine-1-carboxylic acid tert-butyl ester;tert-Butyl (3R)-3-[(methylsulfonyl)oxy]pyrrolidine-1-carboxylate;tert-Butyl (R)-3-(methylsulfonyloxy)pyrrolidine-1-carboxylate;tert-Butyl (R)-3-[(methylsulfonyl)oxy]pyrrolidine-1-carboxylate
• CAS NO: 127423-61-4
• Molecular Formula: C₁₀H₁₉NO₅S
• Molecular Weight: 229.66018
• Mol File: 127423-61-4.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: ethyl 2-chloro-4-ethoxy-nicotinate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 2-chloro-4-ethoxy-nicotinate(127423-61-4)
• EPA Substance Registry System: ethyl 2-chloro-4-ethoxy-nicotinate(127423-61-4)

Safety Data

• Hazardous Substances Data: 127423-61-4(Hazardous Substances Data)

Usage

Uses

Used in Agricultural Applications:
Ethyl 2-chloro-4-ethoxy-nicotinate is used as a pesticide or herbicide for its ability to inhibit the growth of certain pests and weeds. This makes it a valuable ingredient in crop protection products, helping to ensure the health and yield of agricultural crops.
Used in Pharmaceutical Applications:
Ethyl 2-chloro-4-ethoxy-nicotinate is used as a chemical intermediate in the synthesis of pharmaceutical compounds. Its unique structure and functional groups make it a promising candidate for the development of new medications, particularly in the field of medicinal chemistry.

Upstream product

• 109431-87-0 (R)-tert-butyl 3-hydroxypyrrolidine-1-carboxylate 
• 124-63-0 methanesulfonyl chloride 
• 101408-94-0 3R-acetoxypyrrolidine-1-carboxylic acid tert-butyl ester 
• 132945-75-6 (S)-tert-butyl 3-(methylsulfonyloxy)pyrrolidine-1-carboxylate 
• 101469-92-5 (S)-3-hydroxy-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 101385-90-4 (R)-N-benzyl-3-hydroxypyrrolidine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 121-44-8 triethylamine 

Downstream Products

• 127423-62-5 (S)-1-t-butoxycarbonyl-3-(4-methoxybenzylthio)pyrrolidine 
• 273757-02-1 1-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-1H-imidazo[4,5-b]pyridine 
• 273757-03-2 3-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-3H-imidazo[4,5-b]pyridine 
• 73286-70-1 N-(tert-butoxycarbonyl)-3-pyrroline 
• 900572-43-2 (S)-3-o-tolyloxy-pyrrolidine 
• 1017803-19-8 (S)-3-m-tolyloxy-pyrrolidine 
• 188616-79-7 2-[4-[(3S)-1-(tert-butoxycarbonyl)-3-pyrrolidinyl]oxy]phenylacetic acid ethyl ester 
• 125552-56-9 (S)-tert-butyl 3-azidopyrrolidine-1-carboxylate 
• 147081-44-5 (3S)-3-amino-1-(tert-butoxycarbonyl)-pyrrolidine 
• 132945-74-5 (S)-N-tert-butoxycarbonylpyrrolidin-3-yl benzoate 
• 132945-78-9 tert-butyl (S)-3-cyanopyrrolidine-1-carboxylate 
• 859282-12-5 (3S)-3-pyrrolidin-1-ylpyrrolidine 
• 1111078-67-1 tert-butyl (3S)-3-[2-(trifluoromethyl)phenoxy]-pyrrolidine-1-carboxylate 
• 1046809-27-1 benzophenone O-[(S)-N-tert-butoxycarbonyl-3-pyrrolidinyl]oxime 

Relevant articles and documents

6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS

The present disclosure provides 6-heteroaryloxy benzimidazole and azabenzimidazole compounds and compositions thereof useful for inhibiting JAK2.

NITROGEN HETEROCYCLIC COMPOUNDS AND METHODS OF USE

The present disclosure relates to compounds of formula (I): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparing the compounds, compositions comprising the compounds, and methods of using the compounds as inhibitors of receptor tyrosine kinases, in particular oncogenic mutants of ErbB-receptors e.g. in the treatment of cancer.

INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES

Provided herein are heteroaryl inhibitors of fibroblast growth factor receptor kinases, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.

PYRROLO(PYRAZOLO)PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR

The present invention relates to a pyrrolo(pyrazolo)pyrimidine derivative having efficacy as an LRRK2 inhibitor, a preparation method therefor, and a pharmaceutical composition for preventing or treating degenerative brain diseases, containing the same.

Novel pyrrolidine or piperidine derivatives having activity for T-type calcium channel

A pyrrolidine or piperidine compound having activity for T - type calcium channel, wherein the pyrrolidine or piperidine compound of Formula 1 according to the present invention has an excellent antagonistic activity to, T-type calcium channel, and can be used as a preventive or therapeutic agent, for pain diseases, or cancer related to cancer, or cancer such as, epilepsy and,hepatic pain, angina. (by machine translation)

RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided herein are a RET inhibitor, a pharmaceutical composition thereof and uses thereof. In particular, provided is a compound having Formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. Provided is a pharmaceutical composition comprising the compound, and uses of the compound and pharmaceutical composition thereof for the preparation of a medicament, in particular for treatment and prevention of RET-related diseases and conditions, including cancer, irritable bowel syndrome, and/or pain associated with irritable bowel syndrome.

RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided herein are a RET inhibitor, a pharmaceutical composition thereof and uses thereof. In particular, provided is a compound having Formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. Provided is a pharmaceutical composition comprising the compound, and uses of the compound and pharmaceutical composition thereof for the preparation of a medicament, in particular for treatment and prevention of RET-related diseases and conditions, including cancer, irritable bowel syndrome, and/or pain associated with irritable bowel syndrome.

Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype

The bromodomain and extraterminal domain (BET) family of epigenetic regulators comprises four proteins (BRD2, BRD3, BRD4, BRDT), each containing tandem bromodomains. To date, small molecule inhibitors of these proteins typically bind all eight bromodomains of the family with similar affinity, resulting in a diverse range of biological effects. To enable further understanding of the broad phenotype characteristic of pan-BET inhibition, the development of inhibitors selective for individual, or sets of, bromodomains within the family is required. In this regard, we report the discovery of a potent probe molecule possessing up to 150-fold selectivity for the N-terminal bromodomains (BD1s) over the C-terminal bromodomains (BD2s) of the BETs. Guided by structural information, a specific amino acid difference between BD1 and BD2 domains was targeted for selective interaction with chemical functionality appended to the previously developed I-BET151 scaffold. Data presented herein demonstrate that selective inhibition of BD1 domains is sufficient to drive anti-inflammatory and antiproliferative effects.

(S)-N-methyl-N-(pyrrolidin-3-yl)acetamide dihydrochloride and synthesis method therefor

The invention discloses (S)-N-methyl-N-(pyrrolidin-3-yl)acetamide dihydrochloride and a synthesis method therefor and belongs to the technical field of organic chemical synthesis. The synthesis methodcomprises the following procedures: subjecting (R)-3-pyridonyl-1-tert-butyl carboxylate, which serves as a raw material, to reactions of four steps, i.e., methanesulfonate synthesis, methyl amination, acetyl loading and tert-butyloxycarbonyl removing salt forming, thereby obtaining the (S)-N-methyl-N-(pyrrolidin-3-yl)acetamide dihydrochloride. The synthesis method for the (S)-N-methyl-N-(pyrrolidin-3-yl)acetamide dihydrochloride, provided by the invention, is safe, convenient and economical, the obtained (S)-N-methyl-N-(pyrrolidin-3-yl)acetamide dihydrochloride is stable in performance and can be conveniently stored and transported.

SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS

Provided herein are compounds of the Formula I: (I) or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.